CureVac
Develops drugs that allow the human body to fight various diseases.
Enterprise value
$1.3b
Share price
$5.43 CVAC
Company register number
HRB 754041 (Stuttgart)
Recent deals
loading funding rounds…
Baillie Gifford(exited)
DH Capital(exited)
dievini Hopp Biotech holding(exited)
Bill & Melinda Gates Foundation(exited)
LBBW Venture Capital(exited)
European Investment Bank(exited)
KfW(exited)
GSK(exited)
Qatar Investment Authority(exited)
Van Lanschot Kempen(exited)
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 26 % | 181 % | 111 % | (35 %) | (20 %) | 896 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (521 %) | (525 %) | (225 %) | (375 %) | (331 %) | (439 %) | 39 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (554 %) | (573 %) | (265 %) | (400 %) | (369 %) | (484 %) | 30 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 324 % | 248 % | 233 % | 792 % | 93 % | 215 % | 29 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by CureVac
Edit
ACQUISITION by CureVac Jun 2022